The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 25, 2015

Filed:

Nov. 05, 2008
Applicants:

Curtis J. Henrich, Rockville, MD (US);

Heidi R. Bokesch, Frederick, MD (US);

Susan E. Bates, Bethesda, MD (US);

Robert W. Robey, Laurel, MD (US);

Suneet Shukla, Rockville, MD (US);

Suresh V. Ambudkar, Gaithersburg, MD (US);

Michael C. Dean, Frederick, MD (US);

James B. Mcmahon, Frederick, MD (US);

Inventors:

Curtis J. Henrich, Rockville, MD (US);

Heidi R. Bokesch, Frederick, MD (US);

Susan E. Bates, Bethesda, MD (US);

Robert W. Robey, Laurel, MD (US);

Suneet Shukla, Rockville, MD (US);

Suresh V. Ambudkar, Gaithersburg, MD (US);

Michael C. Dean, Frederick, MD (US);

James B. McMahon, Frederick, MD (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/7028 (2006.01); A61K 31/704 (2006.01); C07H 15/252 (2006.01); A61K 36/06 (2006.01); A61K 31/015 (2006.01); A61K 31/28 (2006.01); A61K 31/4155 (2006.01); A61K 31/439 (2006.01); A61K 31/4439 (2006.01); A61K 31/4741 (2006.01); A61K 31/48 (2006.01); A61K 31/505 (2006.01); A61K 31/655 (2006.01); A61K 31/7048 (2006.01);
U.S. Cl.
CPC ...
A61K 36/06 (2013.01); A61K 31/015 (2013.01); A61K 31/28 (2013.01); A61K 31/4155 (2013.01); A61K 31/439 (2013.01); A61K 31/4439 (2013.01); A61K 31/4741 (2013.01); A61K 31/48 (2013.01); A61K 31/505 (2013.01); A61K 31/655 (2013.01); A61K 31/7048 (2013.01);
Abstract

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.


Find Patent Forward Citations

Loading…